Loading
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
Previous close
$7.60
−$0.45 · -5.59%
Regular session · ET · Market data may be delayed.
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
Day range
Current $7.60
52-week range
Current $7.60
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
76
Undervalued
Sentiment
60
Mixed
Risk
70
High Risk
Momentum
28
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
Day range
Current $7.60
52-week range
Current $7.60
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 58.44M USD | 53.49M USD | 42.16M USD | 35.36M USD | 34.46M USD |
| Cost of goods sold | 31.31M USD | 27.64M USD | 21.06M USD | 15.4M USD | 16.63M USD |
| Gross profit | 27.12M USD | 25.85M USD | 21.11M USD | 19.96M USD | 17.83M USD |
| Research and development | 5.62M USD | 5.33M USD | 6.14M USD | 11.81M USD | 12.36M USD |
| Selling, general, and administrative | 45.16M USD | 26.49M USD | 26.1M USD | 27.17M USD | 23.89M USD |
| Operating expenses | 51.7M USD | 36.52M USD | 33.34M USD | 40.13M USD | 37.49M USD |
| Interest income | 91K USD | 103K USD | 85K USD | 17K USD | 34K USD |
| Depreciation and amortization | 4.5M USD | 3.93M USD | 3.52M USD | 3.41M USD | 2.76M USD |
| Operating income | −24.58M USD | −10.67M USD | −12.23M USD | −20.18M USD | −19.65M USD |
| Net income | −34.28M USD | −31.4M USD | −14.38M USD | −19.91M USD | −19.6M USD |
Company facts updated Sep 13, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$11.50
51.32% upsideLimited analyst sample: 3 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI1.38M0.00%2.3T USD0.03%$376.31+0.82%
Vanguard Extended Market ETFVXF573.6K0.00%93.7B USD0.05%$237.76+0.68%
iShares Micro-Cap ETFIWC260.02K0.02%1.44B USD0.60%$190.84+0.39%
Dimensional - US Small Cap ETFDFAS133.29K0.00%15.49B USD0.26%$80.52+0.64%
U.S. Micro Cap Portfolio ETFDFMC89.31K0.00%7.73B USD0.43%$59.13+0.67%
Avantis U.S. Small Cap Equity ETFAVSC8.12K—3.09B USD0.25%$71.48+0.53%
Dimensional - US Core Equity 1 ETFDCOR32.20.00%3.58B USD0.14%$83.91+0.75%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASU.S. Micro Cap Portfolio ETFDFMCAvantis U.S. Small Cap Equity ETFAVSCDimensional - US Core Equity 1 ETFDCORAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
